The hypocretin/orexin system in sleep disorders: preclinical insights and clinical progress

被引：29

作者：

Chow, Matthew ^{[1
]}

Cao, Michelle ^{[1
]}

机构：

[1] Stanford Univ, Dept Psychiat & Behav Sci, Div Sleep Med, Sch Med, 450 Broadway St, Stanford, CA 94063 USA

来源：

NATURE AND SCIENCE OF SLEEP | 2016年 / 8卷

关键词：

hypocretin; orexin; narcolepsy; insomnia; orexin antagonist; orexin agonist; OREXIN RECEPTOR ANTAGONIST; NON-REM; SUVOREXANT; NARCOLEPSY; NEUROPEPTIDES; DISCOVERY;

D O I：

10.2147/NSS.S76711

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Much of the understanding of the hypocretin/orexin (HCRT/OX) system in sleep-wake regulation came from narcolepsy-cataplexy research. The neuropeptides hypocretin-1 and -2/orexin-A and -B (HCRT-1 and -2/OX-A and -B, respectively), as we know, are intimately involved in the regulation wakefulness. The HCRT/OX system regulates sleep-wake control through complex interactions between monoaminergic/cholinergic (wake-promoting) and gamma-aminobutyric acid-ergic (sleep-promoting) neuronal systems. Deficiency of HCRT/OX results in loss of sleep-wake control or stability with consequent unstable transitions between wakefulness to nonrapid eye movement and rapid eye movement sleep. This manifests clinically as abnormal daytime sleepiness with sleep attacks and cataplexy. Research on the development of HCRT/OX agonists and antagonists for the treatment of sleep disorders has dramatically increased with the US Food and Drug Administration approval of the first-in-class dual HCRT/OX receptor antagonist for the treatment of insomnia. This review focuses on the origin, mechanisms of HCRT/OX receptors, clinical progress, and applications for the treatment of sleep disorders.

引用

页码：81 / 86

页数：6

共 37 条

[31]

Schutte-Rodin S, 2008, J CLIN SLEEP MED, V4, P487

[32] Selective blockade of the orexin-2 receptor attenuates ethanol self-administration, place preference, and reinstatement [J].

Shoblock, James R. ;

Welty, Natalie ;

Aluisio, Leah ;

Fraser, Ian ;

Motley, S. Timothy ;

Morton, Kirsten ;

Palmer, James ;

Bonaventure, Pascal ;

Carruthers, Nicholas I. ;

Lovenberg, Timothy W. ;

Boggs, Jamin ;

Galici, Ruggero .

PSYCHOPHARMACOLOGY, 2011, 215 (01) :191-203

[33] Discovery and Characterization of ACT-335827, an Orally Available, Brain Penetrant Orexin Receptor Type1 Selective Antagonist [J].

Steiner, Michel A. ;

Gatfield, John ;

Brisbare-Roch, Catherine ;

Dietrich, Hendrik ;

Treiber, Alexander ;

Jenck, Francois ;

Boss, Christoph .

CHEMMEDCHEM, 2013, 8 (06) :898-903

[34] Effects of Suvorexant, an Orexin Receptor Antagonist, on Sleep Parameters as Measured by Polysomnography in Healthy Men [J].

Sun, Hong ;

Kennedy, William P. ;

Wilbraham, Darren ;

Lewis, Nicole ;

Calder, Nicole ;

Li, Xiaodong ;

Ma, Junshui ;

Yee, Ka Lai ;

Ermlich, Susan ;

Mangin, Eric ;

Lines, Christopher ;

Rosen, Laura ;

Chodakewitz, Jeffrey ;

Murphy, Gail M. .

SLEEP, 2013, 36 (02) :259-267

[35]

von Economo C, 1930, J NERV MENT DIS, V72, P125

[36] Distinct narcolepsy syndromes in Orexin receptor-2 and Orexin null mice:: Molecular genetic dissection of non-REM and REM sleep regulatory processes [J].

Willie, JT ;

Chemelli, RM ;

Sinston, CM ;

Tokita, H ;

Williams, SC ;

Kisanuki, YY ;

Marcus, JN ;

Lee, C ;

Elmquist, JK ;

Kohlmeier, KA ;

Leonard, CS ;

Richardson, JA ;

Hammer, RE ;

Yanagisawa, M .

NEURON, 2003, 38 (05) :715-730

[37] Promotion of Sleep by Suvorexant--A Novel Dual Orexin Receptor Antagonist [J].

Winrow, Christopher J. ;

Gotter, Anthony L. ;

Cox, Christopher D. ;

Doran, Scott M. ;

Tannenbaum, Pamela L. ;

Breslin, Michael J. ;

Garson, Susan L. ;

Fox, Steven V. ;

Harrell, Charles M. ;

Stevens, Joanne ;

Reiss, Duane R. ;

Cui, Donghui ;

Coleman, Paul J. ;

Renger, John J. .

JOURNAL OF NEUROGENETICS, 2011, 25 (1-2) :52-61

← 1 2 3 4 →